CTRI/2010/091/001337已完成3 期
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with T2DM not on an AHA or on any AHA in monotherapy or combination therapy (including oral or non oral agents)
- •Patients with reduced kidney function
排除标准
- •History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy
- •Have proliferative diabetic retinopathy for which treatment is planned during the course of the study
- •Kidney disease that required treatment with immunosuppressive therapy, history of dialysis or kidney transplant, presence of nephrotic syndrome (eg, severe proteinuria with hypoalbuminemia and/or edema), or inflammatory kidney disease
- •Receiving anti hypertensive or anti-hyperlipidemic therapy not on a stable regimen
- •History of a severe hypoglycemic episode within 6 months before screening
研究者
相似试验
进行中（未招募）
不适用
A Randomized Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glucose Control and on Metformin MonotherapySubjects with T2DM with inadequate glycemic control on a maximally effective dose of metformin in monotherapyMedDRA version: 13.1Level: LLTClassification code 10063624Term: Type II diabetes mellitus inadequate controlSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2010-024256-28-CZJanssen Cilag International NV270
进行中（未招募）
不适用
An Efficacy, Safety, and Tolerability Study of Canagliflozin in PatientsWith Type 2 Diabetes Mellitus Who Have Moderate Renal ImpairmentType 2 Diabetes Mellitus with Moderate Renal ImpairmentMedDRA version: 14.0Level: PTClassification code 10062237Term: Renal impairmentSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2009-017136-40-DEJanssen Cilag international NV240
进行中（未招募）
不适用
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal ImpairmentEUCTR2009-017136-40-PLJanssen-Cilag International NV240
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26 Week Multicenter Study with a 26-Week Extension to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 (Canagliflozin) Compared with Placebo in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Pioglitazone Therapy - The CANTATA-MP TrialEUCTR2009-018070-64-PTJanssen-Cilag International NV360
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of GSK573719 Administered Once- and Twice-Daily in Subjects with COPDChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.0Level: LLTClassification code 10010952Term: COPDEUCTR2009-014543-36-DEGlaxoSmithKline Research & Development170